Aratana Therapeutics to Report Second Quarter Results

Conference Call and Webcast scheduled for August 7, 2015, 8:30 a.m. ET

KANSAS CITY, Kan., July 21, 2015 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, will host a conference call and live audio webcast on Friday, August 7, 2015, at 8:30 a.m. ET, to discuss its financial results for the second quarter ended June 30, 2015.

Conference Call Information:
Interested participants and investors may access the conference call by dialing:

  • 1 (866) 364-3820 (U.S.)
  • 1 (855) 669-9657 (Canada)
  • 1 (412) 902-4210 (international)

A replay of the call will be available for 90 days beginning at approximately 10:30 a.m. ET on August 7, 2015. Access numbers for this replay are:

  • 1 (877) 344-7529 (U.S.)
  • 1 (855) 669-9658 (Canada)
  • 1 (412) 317-0088 (international)
  • Conference ID: 10069942

An audio webcast will be also accessible via the Investors Relations section of the Aratana Therapeutics website The webcast replay will also remain available for 90 days.

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The company's pipeline includes therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious medical conditions.  Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit


For investor inquires:
Aratana Therapeutics, Inc.
Craig Tooman; (913) 353-1026

For media inquiries:
Tiberend Strategic Advisors, Inc.
Andrew Mielach; (212) 375-2694

SOURCE Aratana Therapeutics, Inc.

print email rss